Protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in the tumorigenesis and progression of multiple tumors, and has been shown to be important therapeutic targets for cancer. The present study aimed to explore the role and molecular mechanisms of AKT/mTOR pathway in human hemangioma (HA). Twenty-five cases of human HA tissues were collected. The expression of AKT, mTOR and proliferating cell nuclear antigen (PCNA) proteins was evaluated using semi-quantitative immunohistochemistry in biopsy samples in different phases of HA. AKT/mTOR pathway was blocked by recombinant small hairpin RNA adenovirus vector rAd5-AKT+mTOR (rAd5-Am), used for infecting proliferating phase HA-derived endothelial cells (HDEC). The expression of AKT, mTOR and PCNA was detected by Real-time PCR and Western blot assays. Cell proliferative activities were determined by MTT assay, and cell cycle distribution and apoptosis were analyzed by flow cytometry. As a consequence, the expression of AKT, mTOR and PCNA was significantly increased in proliferative phase HA, while that was decreased in involutive phase. Combined blockade of AKT/mTOR pathway by rAd5-Am diminished cell proliferative activities, and induced cell apoptosis and cycle arrest with the decreased expression of AKT, mTOR and PCNA in proliferative phase HDEC. In conclusion, the activity of AKT/mTOR pathway was increased in proliferative phase HA, while it was decreased in involutive phase. Combined blockade of AKT/mTOR pathway might suppress cell proliferation via down-regulation of PCNA expression, and induce apoptosis and cycle arrest in proliferative phase HDEC, suggesting thatAKT/mTOR pathway might represent the important therapeutic targets for human HA.
still lacking. Therefore, identification of key genes and targets related to HA is crucial for diagnosis and prevention of HA.
Activated phosphoinositide 3-kinase (PI3K)/ AKT signaling appears to be an obligate event in the development of cancer. The highly related members of the mammalian FoxO transcription factor family represent one of several effector arms ofPI3K1AKT signaling, and regulate endothelial cell morphogenesis and vascular homeostasis (4) . The activation of transcription-3, AKT, and cyclinDI is over-expressed in angiosarcoma (5) . The expression of distinct signaling abnormalities, such as reactive oxygen, NF-KB and AKT is increased in malignant vascular tumors, including hemangioendothelioma and angiosarcoma (6) . HoxA5 increases AKT1 expression and further enhances AKT activity via a coordinate down-regulation ofPTEN, demonstrating a central role in coordinating a stable vascular phenotype (7) . In primary hemangioblastomas, receptor tyrosine kinase signaling predominantly involves EGFRlPI3K1AKT pathway, providing an attractive molecular target for therapeutic intervention (8) . In addition, mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo (9) , and aberrant mTOR signaling may playa role in the development ofHA, the vascular nature of which may be due partially to high levels of VEGF caused by dysregulation of mTOR signaling (10) .
Proliferating cell nuclear antigen (PCNA) is expressed by the majority of endothelial cells and pericytes in the proliferative phases, but its expression was negligible in the involutive phase (11). PCNA can be expressed in child proliferative HA and involutive HA or all of adult HA, and in 80% of arteriovenous malformations and 85% of cavernomas (12) . The frequency of PCNA positive staining shows active proliferation of the tumor cells in hemangiosarcoma that occurs naturally in the pancreas (13) , but shows a low proliferative activity in kaposiform hemangioendothelioma (14) . The immunostaining levels of CD34, VEGF and PCNA are elevated in HA, supporting that HA has biological characteristics of angiogenic histogenetic tumor, and anti-angiogenic therapy may represent a novel strategy for the treatment ofHA (15) .
However, to date, the expression of AKT/mTOR pathway in different phases of HA has not been comprehensively explored. In the present study, the expression ofAKT, mTOR and PCNA was evaluated using semi-quantitative immunohistochemistry in biopsy samples A loss-of-function approach was used to investigate the effects of blockade of AKT/ mTOR pathway on the proliferative activities, and cell apoptosis and cycle distribution in proliferative phase HDEC..
MATERIALS AND METHODS

Materials
The proliferative phase HDEC used in the experiments was from the Institute of Biochemistry and Cell Biology (Shanghai, China). The adenovirus vector rAdS-Am, negative control vector and virion-packaging elements were from Genechem (Shanghai, China). The primers of AKT, mTOR and PCNA were synthesized by ABI (USA). All antibodies were from Santa Cruz Biotechnology (USA).
Drugs and reagents
Dulbecco's Modified Eagle medium (DMEM) and fetal bovine serum (FBS) were from Thermo Fisher Scientific Inc (Waltham, MA, USA); Tklzol Reagent and Lipofectamine 2000 were from Invitrogen (Carlsbad, CA, USA); M-MLV Reverse Transcriptase was from Promega (Madison, WI, USA); SYBR Green Master Mixture was from Takara (Otsu, Japan). ECL-PLUSlKit was from GE Healthcare (Piscataway, NJ, USA). Cell cycle analysis kit and apoptosis kit (Propidium Iodide (PI), RNase A, Annexin V-FITC) were from KeyGEN biology (Nanjing, China).
Tissue samples
Twenty-five freshly resected human HA samples were collected at the Department of General Surgery, Xinhua Hospital, and were classified according to Mulliken criteria. Tissues and clinical information were obtained as part ofan approved study at Shanghai Jiao Tong University. There were 13 cases of proliferative phase HA and 12 cases of involutive phase HA. A portion of each tissue sample was fixed with 10% formalin for histopathological and immunohistochemical examination. All HA tissues were diagnosed by two independent pathologists.
Immunohistochemical staining
Immunostaining for AKT, mTOR and PCNA using monoclonal antibodies was performed. Unstained sections were deparaffinized and incubated overnight at 4°C with primary antibodies against the proteins, then with biotinylated secondary antibody (l :200) at room temperature for 1 h, followed by incubation with ABC peroxidase and 3,3' diaminobenzidine (DAB; 30 mg dissolved in 100 ml Tris-buffer containing 0.03% HP).
Sections were counterstained with hematoxylin. Digital images were acquired and the integrated optical density (IOD) of semi-quantitative analysis was performed.
Cell culture and transfection
The proliferative phase HDEC were cultured in DMEM medium supplemented with 10% heat-inactivated FBS, 100U/ml ofpenicillin and 1OOllg/ml ofstreptomycin. They were all placed in a humidified atmosphere containing 5% CO 2 at 37°C. The adenovirus rAd5-Am was transfected into proliferative phase HDEC. Cells were subcultured at a 1:5 dilution in 300 ug /ml G418-containing medium. Positive stable transfectants were selected and expanded for further study. The clone in which the rAd5-Am vectors transfected was named as rAd5-Am group, the negative control vectors transfected was named as NC group.
Quantitative real-time PCR
Real-time PCR was used to quantitatively determine the mRNA expression levels ofAKT, mTOR and PCNA in proliferative phase HDEC. Total RNA of each clone was extracted with TRIzol according to the manufacturer's protocol. Reverse-transcription was carried out using M-MLV and eDNA amplification was carried out using SYBRGreen Master Mixkitaccording tothe manufacturer 's protocol. Target genes were amplified using specific oligonucleotide primer and human glyceraldehyde-3phosphate dehydrogenase (GAPDH) gene was used as an endogenous control. The PCR primer sequences were as follows: AKT, 5'-TAGGTGTGGATGGTTGCAGA-3' and 5'-CTCCCACAGACCCAGAACAT-3'; mTOR,5' -CCCAAGCTTGAACCTCAGGGCAAG ATGCT-3' and 5'-GCTCTAGATTAGATCCAAAGC CCCTAAAAGC-3'; PCNA, 5' -CCATCCTCAAGAAGGTGTTGG-3' and 5'-GTGTCCCATATCC GCAATTTTAT-3'; GAPDH, 5' -CAACGAATTTGGCTACAGCA-3' and 5'-AGGGGTCTACAT GGCAACTG-3'. Data were analyzed using the comparative Ct method (20DD Ct). Three separate experiments were performed for each clone.
Western blot assay
The proliferative phase HDEC was harvested and extracted using lysis buffer (Tris-HCI, SDS, Mercaptoethanol, Glycerol). Cell extracts were boiled for 5 min in loading buffer and then equal amount of cell extracts were separated on 15% SDS-PAGEgels. Separated protein bands were transferred into polyvinylidene fluoride (PVDF) membranes and the membranes were blocked in 5% skim milk powder. The primary antibodies against AKT, mTOR and PCNA were diluted according to the instructions of antibodies and incubated overnight at 4°C. Then, horseradish peroxidase-linked secondary antibodies were added at a dilution ratio of 1:1000, and incubated at room temperature for 2 h. The membranes were washed three times with PBS and the immunoreactive bands were visualized using ECL-PLUSlKit according to the kit's instruction. The relative protein level in different cell lines was normalized to GAPDH concentration. Three separate experiments were performed for each clone.
Cell proliferation assay
Cell proliferation was analyzed with the MTT assay. Briefly, cells infected with rAd5-Am were incubated in 96-well-plates at a density of 1x10 5 cells per well with DEME medium supplemented with 10% FBS. Cells were treated with 20 III MTT dye at 0, 24 h, 48 hand 72 h, and then incubated with 150 III of DMSO for 5 min. The color reaction was measured at 570 om with enzyme immunoassay analyzer (Bio-Rad, American). The proliferation activity was calculated for each clone.
Cell apoptosis analysis
To detect cell apoptosis, the proliferative phase HDEC was trypsinized, washed with cold PBS and resuspended in binding buffer according to the manufacturer's instructions. FITC-AnnexinV and PI were added to the fixed cells for 20 min in darkness at room temperature. Then, Annexin V binding buffer was added to the mixture before the fluorescence was measured on FACsort flow cytometer. The cell apoptosis was analyzed using the Cell Quest software (Becton Dickinson, USA). Three separate experiments were performed for each clone.
Cell cycle analysis
To detect cell cycle variation, the proliferative phase HDEC was trypsinized, washed by PBS and fixed with 80% cold ethanol overnight at -20°C. After PBS washing, the fixed cells were stained with PI in the presence of RNase A for 30 min at room temperature in darkness. Each sample was filtered through a 50 urn nylon filter to obtain single-cell suspension. The samples were then analyzed on FACsort flow cytometer (Becton Dickinson, Mountain View, CA, USA). ModFit3.0 software (Verity Software House, Topsham, ME, USA) was used for cell cycle analysis. Three separate experiments were performed for each clone.
Statistical analysis
SPSS 13.0 was used for the statistical analysis. Oneway analysis of variance (ANOVA) was used to analyze the differences between groups. The LSD method of multiple comparisons was used when the probability for ANOVA was statistically significant. Statistical significance was P<O.05.
RESULTS
Pathologic and morphologic changes in different phases ofhuman HA
The pathologic and morphologic changes were varied in different phases ofhuman HA. As shown in Fig. I , in proliferative phase HA, the cell mass was present with expansive growth and clear boundaries, but with irregular shapes and less tissue intervals. The microvessels were in different diameter sizes, arranged in disorder, and the cell nuclei of HA was large with deep staining. However, in involutive phase HA, the cell mass had unclear boundaries and more tissue intervals. Many microvessels appeared with irregular sinusoid-like changes, and HA cells were loose in disorder, and part of them formed a microvascular group with honeycomb-like changes.
Expression of AKT, mTOR and PCNA in different phases ofhuman HA
The expression of AKT, mTOR and PCNA proteins was evaluated using immunochemical staining. As shown in Fig. 2 , the positive expression ofAKT, mTOR and PCNA in proliferative phase HA was significantly higher than the involutive phase HA (each **P<O.OI).
Effect ofrAd5-Am on AKT and mTOR expression
To define whether the expression of AKT and mTOR was knocked down by rAd5-Am in proliferative phase HDEC, the expression levels of AKT and mTOR mRNA were measured by Real-time PCR. As shown in Fig. 3A , an obvious inhibition of AKT and mTOR expression was observed in the rAd5-Am group compared with the NC group (each**P<O.OI). The expression levels of AKT and mTOR proteins, indicated by Western blot assay, were markedly down-regulated in the rAd5-Am group compared to the NC group in proliferative phase HDEC (each **P<O.OI) (Fig. 3, B-D) .
Effect ofrAd5-Am on HDEC growth
In order to investigate the effect of rAd5-Am on cell growth in proliferative phase HDEC, we examined the proliferative activities of HDEC by MTT. As a result, rAd5-Am could significantly reduce the proliferative activities ofHDEC in a timedependent manner compared with the NC group (Fig. 4A ). In addition, to determine whether rAd5-Am suppressed the endogenous expression ofPCNA through translational repression, the expression of PCNA protein was examined by Western blot. The amount ofPCNA protein was significantly decreased in the rAd5-Am group compared with the NC group (**P<O.OI) (Fig. 4, B-C expression.
Effects of rAd5-Am on HDEC apoptosis and cycle distribution
To determine whether rAd5-Am affected the apoptosis and cycle distribution in proliferative phase HDEC, flow cytometric analysis was performed, The apoptotic index of HDEC in the rAd5-Am group was significantly higher than the NC group (**P<O.OI) (Fig. 5, A, C) . The cycle distribution of HDEC showed that, the GiG, phase fraction was increased, while Sand G/M phase fractions were decreased. Cell cycle was arrested in GiGl phase in rAd5-Am group compared with the NC group (Fig.  5B, D) , indicating that blockade of AKT/mTOR pathway might induce apoptosis and cycle arrest in proliferative phase HDEC.
DISCUSSION
Polyoma middle T (PYMT) as an oncogene transforms endothelial cells and hematopoietic stem cells, which exhibit activation of the PI3K1 AKT and mTOR pathways, suggesting a mechanism used by PYMT to transform endothelial progenitors (16) . Mutations in CCMI, CCM2, or CCM3 lead to cerebral cavernous malformations, of which CCM3 supports AKT-mediated endothelial cell quiescence and survival, showing the importance of CCM3/ AKT pathway in neural/vascular interactions within the neurovascular unit (17, 18) . However, there is some controversy about the expression of PCNA in HA. Though many studies have conformed the high expression ofPCNA in human HA (19) , others indicate no correlation between PCNA and HA (20) . It is indispensible to clarify the expression of AKT, mTOR and PCNA in HA. In the present study, on the one hand, we found that the pathologic and morphologic changes were varied in proliferative and involutive phase HA. On the other hand, we proved that AKT, mTOR and PCNA were highly expressed in proliferative phase HA, while these were lowly expressed in involutive phase HA.
Interestingly, in tenns of the important roles of AKT/ mTOR pathway in HA, some drugs have been found effective in treatment of severe HA through inhibition of the pathway. Propranolol exerts suppressive effects on HA through PI3K1AKT pathway, which provides a plausible mechanism for HA regression (21) . Bleomycin inhibits the development of HA via inactivation of AKT, which may represent an important therapeutic target for HA (22) . Sirolimus, an mTOR inhibitor, has been demonstrated to exert anti-angiogenic activity in kaposifonn hemangioendotheliomas and complicated vascular malformations (23, 24) . Rapamycin targets the self-renewal and vascular differentiation potential in patient-derived HA stem cells, suggesting a novel therapeutic strategy to prevent formation of HA (25, 26) . However, little information has been reported on the role and molecular mechanisms of AKT/mTOR pathway in HA. In our study, a loss-of-function experiment showed that combined blockade of AKT/mTOR pathway inhibited growth and induced apoptosis and cycle arrest in proliferative phase HDEC, and provided new therapeutic targets for treatment of humanHA.
However, how AKT/mTOR pathway regulates the PCNA expression in HA is still unclear. Our findings indicated that combined blockade of AKT/ mTOR pathway led to the decreased expression of PCNA in proliferative phase HDEC. PCNA is a nuclear protein that is expressed in proliferating cells, required for maintaining cell proliferation and used as a marker for cell proliferation of HA (27) . Some studies have shown that targeting AKT/ mTOR pathway depletes the proliferation of skin carcinogenesis through down-regulation of PCNA (28) . The agents, such as vicenin-2, inhibit EGFR/ Akt/mTOR pathway via decrease of PCNA and CyclinDI expression in prostate cancer (29) . We also demonstrated that combined blockade of AKT/ mTOR pathway inhibited the growth in proliferative phase HDEC through down-regulation of PCNA expression, filling the study gaps about the regulation ofAKT/mTOR pathway on PCNA expression in HA.
In conclusion, the activity of AKT/mTOR pathway is increased in proliferative phase HA, while that is decreased in involutive phase. Combined blockade of AKT/mTOR pathway suppresses cell proliferation and induces apoptosis and cycle arrest in proliferative phase HDEC via down-regulation of PCNA expression. AKT/mTOR pathway may represent the important therapeutic targets for human HA.
